SCHEMBL20122939

SCHEMBL20122939

Cc1nccc2c3cc(Cl)cc(-c4ccc(C#N)nc4)c3n(CC3CC3)c12

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.38
MAOA P21397 1/20 0.38
DYRK1A Q13627 1/20 0.38
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
VHL P40337 1/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
GRM2 Q14416 3/20 0.34
CRHR1 P34998 1/20 0.34
PDE10A Q9Y233 1/20 0.34
ACHE P22303 1/20 0.34
KDM1A O60341 2/20 0.33
RET P07949 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20122759 0.87 DYRK1A (0.38) MAOADYRK1AHDAC1HDAC6GRM2
SCHEMBL30664235 0.83 HDAC1 (0.35) MAOADYRK1AHDAC1HDAC6CRHR1
SCHEMBL20122880 0.83 HDAC1 (0.35) MAOADYRK1AHDAC1HDAC6CRHR1
SCHEMBL30664227 0.83 DYRK1A (0.45) MAOADYRK1AHDAC1HDAC6ACHE
SCHEMBL20122960 0.83 DYRK1A (0.45) MAOADYRK1AHDAC1HDAC6ACHE
SCHEMBL20122737 0.83 RET (0.40) PIK3CAHDAC1HDAC6CRHR1RET
SCHEMBL20122937 0.82 BRD4 (0.37) MAOADYRK1AHDAC1HDAC6CRHR1
SCHEMBL30664292 0.82 BRD4 (0.37) MAOADYRK1AHDAC1HDAC6CRHR1
SCHEMBL29756567 0.81 DYRK1A (0.35) MAOADYRK1AHDAC1HDAC6GRM2
SCHEMBL20122744 0.81 RET (0.42) DYRK1AHDAC1HDAC6JAK2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
CN-110382496-B Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders 赛诺菲 2022-08-09 CN disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 PIK3CA 1083/4885MAOA 245/4885DYRK1A 493/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 PIK3CA 1083/4885MAOA 245/4885DYRK1A 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.